Kalos Management’s Amicus Therapeutics FOLD Stock Holding History

Kalos Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,150	Closed	-$153K	–	235
2020 Q2	$153K	Hold	10,150	–	–	0.06%	196
2020 Q1	$93K	Hold	10,150	–	–	0.04%	190
2019 Q4	$98K	Sell	10,150 -700	-6%	-$6.41K	0.04%	192
2019 Q3	$87K	Hold	10,850	–	–	0.03%	187
2019 Q2	$135K	Buy	10,850 +3,194	+42%	+$40.5K	0.06%	178
2019 Q1	$104K	Sell	7,656 -3,094	-29%	-$37.8K	0.07%	152
2018 Q4	$117K	Hold	10,750	–	–	0.06%	179
2018 Q3	$126K	Buy	+10,750	New	+$150K	0.07%	153
2018 Q1	–	Sell	-10,750	Closed	-$154K	–	153
2017 Q4	$154K	Buy	+10,750	New	+$148K	0.07%	198

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Kalos Management's FOLD Position: Q3 2020 in Review

Kalos Management sold out of Amicus Therapeutics (FOLD) in Q3 2020, closing a stake of 10,150 shares — an estimated $153K sold.

Kalos Management first reported a position in FOLD in Q4 2017 and held it in 9 quarters. The position peaked at $154K in Q4 2017. 251 funds tracked by Wall St. Rank hold FOLD as of Q3 2020.

Kalos Management reported no remaining Amicus Therapeutics position as of Q3 2020 after selling out during the quarter.
Kalos Management sold 10,150 Amicus Therapeutics shares in Q3 2020, an estimated $153K.
Kalos Management first reported a position in Amicus Therapeutics in Q4 2017 and held it in 9 quarters.
Kalos Management's Amicus Therapeutics position peaked at $154K in Q4 2017.
251 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2020.

Based on Kalos Management's 13F filing for Q3 2020, filed 12 Nov 2020.